An exhaustive research report titled “Bioengineered Protein Drugs Market – Global Industry Analysis, Share, Size, Trends, Growth and Forecasts 2017-2025” has been added to the repository of Market Research Reports Search Engine that provides research studies on several domains with real-time data analysis. The research report on the global bioengineered protein drugs market focuses on the main challenges, drivers, trends, developments, and opportunities within the market along with detailed forecasting of the global market projected from 2017 to 2025. The research revolves around chief regions with the analyses of which an entire market scenario is portrayed in this research report. Geographies of North America, Asia-Pacific, Europe, Latin America and Middle East and Africa (MEA) are covered. The global market is segmented in detail covering all major categories that impact the growth of the global market.
Global Bioengineered Protein Drugs Market: Dynamics
The global market for bioengineered protein drugs is influenced by many aspects. The main factor driving revenue growth is the increasing prevalence of diabetes, infectious diseases, cancer, autoimmune disorders, etc. The main characteristics present in bioengineered protein drugs is the higher effectiveness of these drugs with no or negligible side effects as compared to other drugs used to treat diabetes, infectious diseases, cancer and other related disorders. This has pushed bioengineered protein drugs consumption, which contributes to the growth of the global market for bioengineered protein drugs. Several companies are investing in the research to develop innovative bioengineered protein drugs. However, high manufacturing costs incurred in bioengineered protein drugs and a short shelf life along with introduction of biosimilars pose challenges to the growth of the global market.
Global Bioengineered Protein Drugs Market: Key Segmental Takeaways
The global market for bioengineered protein drugs is segmented by drug type into monoclonal antibodies (rituxan, humira, avastin, remicade, herceptin, enbrel, lucentis, synazis and others), by therapeutic proteins into hormones, cytokines, enzyme therapy, blood factor, thrombolytics, by vaccines, by disease condition into diabetes, cancer, autoimmune disorder, hematopoiesis, infectious disease, neurodegenerative, CVD and others, by end user into CROs, pharma & biotech companies and academics, and by region.
- Therapeutic protein segment by drug type is anticipated to hold significant market share owing to intensive activities in products in recombinant DNA technology and engineering of therapeutic proteins
- The vaccines segment by drug type is poised to grow at a higher growth rate and register a high CAGR thus outpacing all other segments by drug type due to the progress in bioengineered therapeutics and prophylactic vaccines
- North America is expected to stay dominant in the global market owing to high cancer instances, and is anticipated to be valued at about US$ 161 Bn by the end of 2025. This region is poised to register a CAGR of 7.2% throughout the assessment period 2017-2025
- Asia-Pacific region is likely to grow at the highest growth rate to register a CAGR of 9.0% during the period of assessment 2017-2025. This high growth rate is mainly due to the contribution of China, India and South Korea, which are characterized by rapid growth in healthcare infrastructure, high prevalence of cancer and huge investments by players involved in bioengineered protein drugs
Global Bioengineered Protein Drugs Market: Forecast
The global market for bioengineered protein drugs is anticipated to witness significant growth and is estimated to be valued at about US$ 337 Bn by 2025 end from a value of around US$ 177 Bn in 2016. It is anticipated to grow at a robust growth rate to register a CAGR of 7.4% throughout the period of assessment.
Global Bioengineered Protein Drugs Market: Competition Scenario
This research report presents in-depth analysis on the various key players present in the market in a separate competitive scenario section. Tier companies such as ProBioGen AG, Panacea Biotec, Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, Sanofi, Eli Lilly and Company, Biocon Ltd., Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Bayer AG, Amgen Inc., F. Hoffmann-La Roche Ltd., and Abbott Laboratories are profiled in this research report.
Enquire About this Report@ https://www.mrrse.com/enquiry/3242
Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Read More Industry News At: https://www.industrynewsanalysis.com/